Business Context and Reporting Period
VistaGen Therapeutics, Inc. filed this Form 8-K on December 22, 2011, to report the entry into a Material Definitive Agreement and the issuance of unregistered equity securities. The company is a Nevada corporation headquartered in South San Francisco, California.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The transaction reported involved no cash proceeds to the Company.
Material Changes
- Stock Exchange: On December 22, 2011, the Company entered into an agreement with Platinum Long Term Growth VII, LLC ("Platinum") to convert 484,000 shares of Common Stock into 45,980 shares of newly created Series A Preferred Stock.
- Conversion Ratio: Each share of Series A Preferred is convertible into 10 shares of Common Stock. The exchange ratio resulted in the Preferred Stock being convertible into the equivalent of 0.95 shares of Common Stock for every share surrendered.
- Capital Structure: The Company authorized the issuance of up to 500,000 shares of Series A Preferred. The Series A Preferred ranks prior to Common Stock for liquidation preferences.
- Dividend Rights: Holders of Series A Preferred are entitled to receive dividends equal to the dividend declared on the number of Common Stock shares into which the Preferred Stock is convertible.
- Voting Rights: Series A Preferred has no voting rights except for transactions requiring a separate class vote.
Guidance, Outlook, and Risks
The filing contains no management guidance, outlook, or discussion of risks and contingencies. The transaction was executed without registration under the Securities Act of 1933, relying on exemptions under Section 3(a)(9) and/or Section 4(2), as Platinum is an accredited investor.
Investor Verification Checklist
- Verify the full terms of the Series A Preferred Stock in the Certificate of Designation (Exhibit 3.1).
- Confirm the impact of the 484,000 share reduction in Common Stock on total outstanding shares.
- Review the liquidation preference formula to understand the payout priority relative to Common Stock.
- Check for any subsequent filings regarding the conversion of the Series A Preferred back to Common Stock.